Using a new approach to treat acute myeloid leukemia
Targeting FTO to treat acute myeloid leukemia
['FUNDING_R01'] · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · NIH-10741801
This study is looking at a new way to treat acute myeloid leukemia (AML) by blocking a specific enzyme called FTO, which helps the cancer grow, to see if it can make leukemia cells less likely to survive, especially in patients whose cancer doesn't respond well to current treatments.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE (nih funded) |
| Locations | 1 site (DUARTE, UNITED STATES) |
| Trial ID | NIH-10741801 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel treatment for acute myeloid leukemia (AML) by targeting a specific enzyme called FTO, which plays a critical role in the disease's progression. The study investigates how inhibiting FTO can affect the survival and growth of leukemia cells, particularly those that are resistant to current therapies. By utilizing a selective small-molecule inhibitor, researchers aim to improve treatment outcomes for patients with FTO-high AML, which represents a significant portion of AML cases. The approach is based on understanding the molecular mechanisms of RNA modifications that influence cancer cell behavior.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia, particularly those whose cancer exhibits high levels of FTO.
Not a fit: Patients with other types of leukemia or those whose AML does not express high levels of FTO may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with acute myeloid leukemia, potentially improving survival rates.
How similar studies have performed: Previous research has shown promising results in targeting RNA modifications for cancer treatment, indicating potential success for this novel approach.
Where this research is happening
DUARTE, UNITED STATES
- BECKMAN RESEARCH INSTITUTE/CITY OF HOPE — DUARTE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHEN, JIANJUN — BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
- Study coordinator: CHEN, JIANJUN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.